Most patients don’t stay on the first stimulant we try. Here’s how to switch safely, without the confusion.

Part 1: Med Fact Book Mini-Series

Working with young adults who are navigating ADHD is rarely straightforward. They’re often dealing with more than just distractibility or missed deadlines. There’s anxiety, identity shifts, life transitions, and sometimes a long history of feeling misunderstood. This isn’t about checking boxes on a symptom list, it’s about understanding how their brain, their environment, and their story all interact. Today, we’re going to unpack that. 

A reminder that focus problems don’t always mean ADHD. That suffering doesn’t always need a label. And that quick relief can sometimes do lasting harm.

How do we assess and treat young adults with ADHD? Dr. Gene Beresin shares practical guidance on neuropsychological testing, biopsychosocial treatment planning, helping teens transition to college and work, understanding brain maturation, and addressing the unique challenges facing Gen Z with ADHD.

Where is ADHD care today? This comprehensive update covers the latest stimulant formulations, nonstimulant innovations, and digital therapeutics. We also provide evidence-based approaches for managing ADHD with common comorbidities including anxiety, depression, autism, bipolar disorder, and psychosis.

GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know.

At Carlat Publishing, we regularly debate trends in psychiatry—and neurodivergence is one of today’s most charged topics.
Let’s call it opinion divergence: Some on our team feel that the DSM-5 term “autism spectrum disorder” is politically insensitive. Others see it as clinically essential.

Today, we’re tackling a big question: How young is too young to treat children with medication for ADHD?